Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for rare, severe psoriasis

NCT ID NCT06295692

Ongoing Disease control Sponsor: Janssen Pharmaceutical K.K. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This phase 3 trial tests an oral drug called JNJ-77242113 in 19 people with two rare and severe forms of psoriasis: generalized pustular psoriasis and erythrodermic psoriasis. The study measures how many participants see improvement after 16 weeks of treatment. It is an open-label study, meaning everyone knows they are getting the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
JNJ-77242113 (an oral tablet)
What this could lead to
If successful, this could provide a new oral treatment option for people with severe, rare forms of psoriasis that are hard to manage.
What could go wrong
This is a small, open-label study with only 19 participants, so results may not apply to everyone. The drug may not work as well in larger groups or have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERYTHRODERMIC PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

generalized pustular psoriasis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ERYTHRODERMIC PSORIASIS GENERALIZED PUSTULAR PSORIASIS

Contacts and locations

Locations

  • Dokkyo Medical University Hospital

    Shimotsuga Gun, 321 0293, Japan

  • Fujita Health University Hospital

    Toyoake, 470-1192, Japan

  • Hospital of the University of Occupational and Environmental Health

    Kitakyushu-shi, 807-8556, Japan

  • Ichinomiya Municipal Hospital

    Ichinomiya, 491-8558, Japan

  • JR Sapporo Hospital

    Hokkaido, 060-0033, Japan

  • Kumamoto University Hospital

    Kumamoto, 860-8556, Japan

  • Mie University Hospital

    Tsu, 514 8507, Japan

  • Nagoya City University Hospital

    Nagoya, 467 8602, Japan

  • Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital

    Osaka, 550 0006, Japan

  • Teikyo University Hospital

    Itabashi Ku, 173 8606, Japan

  • Tohoku University Hospital

    Sendai, 980 8574, Japan

  • Tokyo Medical University Hospital

    Shinjuku, 160 0023, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.